Crispr Therapeutics AG (CRSP) stock is up 125.79% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver’s proprietary ranking system, gives CRSP stock a score of 29 out of a possible 100.
That rank is primarily influenced by a fundamental score of 21. In addition to the average rating from Wall Street analysts, CRSP stock has a mean target price of 163.8. This means analysts expect the stock to fall 1.28% over the next 12 months. CRSP's rank also includes a short-term technical score of 30. The long-term technical score for CRSP is 35.
What's Happening with CRSP Stock Today
Crispr Therapeutics AG (CRSP) stock is up 10.26% while the S&P 500 is up 0.05% as of 1:31 PM on Wednesday, Jun 30. CRSP is up $15.43 from the previous closing price of $150.49 on volume of 4,172,317 shares. Over the past year the S&P 500 is higher by 38.51% while CRSP is up 125.79%. CRSP lost -$5.62 per share in the over the last 12 months.